Product Information
Registration Status: ActiveDEXMEDETOMIDINE KABI INJECTION 100MCG/ML is approved to be sold in Singapore with effective from 2017-06-12. It is marketed by FRESENIUS KABI (SINGAPORE) PTE LTD, with the registration number of SIN15269P.
This product contains Dexmedetomidine 100mcg/ml in the form of INJECTION. It is approved for INTRAVENOUS use.
This product is manufactured by GLAND PHARMA LTD in INDIA.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Description
An agonist of receptors, adrenergic alpha-2 that is used in veterinary medicine for its analgesic and sedative properties. It is the racemate of dexmedetomidine. [PubChem]
Indication
For sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting, also used in pain relief; anxiety reduction and analgesia
Mechanism of Action
Dexmedetomidine is a specific and selective alpha-2 adrenoceptor agonist. By binding to the presynaptic alpha-2 adrenoceptors, it inhibits the release if norepinephrine, therefore, terminate the propagation of pain signals. Activation of the postsynaptic alpha-2 adrenoceptors inhibits the sympathetic activity decreases blood pressure and heart rate.
Clearance
* 39 L/h [Healthy volunteers receiving IV infusion (0.2-0.7 mcg/kg/hr)]
Active Ingredient/Synonyms
(+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole | (+)-medetomidine | (S)-medetomidine | Dexmedetomidin | Dexmedetomidina | Dexmédétomidine | Dexmedetomidinum | Dexmedetomidine |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.